Ozempic Alternatives in 2026: 11 Options Compared by Cost

Most people typing "Ozempic alternatives" into a search bar are not asking a clinical question. They are asking a cost question, an access question, or a side-effect question. Ozempic lists at $1,027.51 per fill before discounts,¹ and the FDA only approves it for Type 2 diabetes,² which means commercial insurance often refuses to cover it for weight loss. The good news in 2026 is that the list of real alternatives has actually grown, not shrunk, despite the spring 2025 FDA enforcement-discretion deadlines that ended broad compounding of branded GLP-1 copies. Below are the eleven options patients realistically choose between, ranked roughly by cost, with what each one is, what it costs, and what the evidence shows.

Why people look beyond Ozempic

Search volume for "Ozempic alternatives" runs about 16,000 monthly US searches per Ahrefs, with traffic potential closer to 21,000 once related queries are included. The query is informational and branded, not safety-driven. The reasons readers give in surveys, comments, and pharmacy intake forms cluster into four buckets:

• Cost. Ozempic's manufacturer list price is $1,027.51 per fill.¹ Without insurance, that runs over $12,000 a year. Commercial insurance typically covers Ozempic only for Type 2 diabetes, not weight management.
• Insurance friction. Even patients with Type 2 diabetes face prior authorization, step therapy (a cheaper drug must be tried first), or formulary exclusions. Medicare Part D covers GLP-1s for diabetes but not for weight loss as of April 2026.
• Supply. Ozempic and Wegovy were on the FDA shortage list from 2022 through early 2025. Patients who lost their refill rhythm during the shortage often migrated to compounded alternatives and stayed there.
• Side effects and tolerability. Nausea, vomiting, constipation, and reflux are the most common discontinuation reasons. Some patients prefer an oral pill (Rybelsus) or a non-GLP-1 mechanism rather than another injectable.

None of those motivations point toward "give up on the medication class." They point toward "find a version that fits my budget, my insurance, and my body." That framing matters because most listicles on this keyword push readers toward brand-name Wegovy or Zepbound as the only respectable answers. The actual choice set is wider. If your question is more narrowly "which weight-loss injection should I pick," see our guide to the best injection for weight loss in 2026, which compares Zepbound, Wegovy, and Saxenda head-to-head on efficacy, cost, and access.

Prescription GLP-1 alternatives

Six prescription drugs share Ozempic's general mechanism, an injectable or oral GLP-1 receptor agonist that slows gastric emptying, blunts appetite, and improves insulin response. They differ in molecule, dose route, FDA indication, and cost.

Wegovy (semaglutide for weight loss)

Wegovy is the same molecule as Ozempic, made by the same manufacturer (Novo Nordisk), at a higher maintenance dose (2.4 mg weekly vs. Ozempic's 1.0 or 2.0 mg). The FDA approved Wegovy on June 4, 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.³ In the phase 3 STEP-1 trial, 1,961 adults on Wegovy lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo.⁴

List price runs $1,349.02 per package.⁷ Through Novo Nordisk's NovoCare Pharmacy direct cash-pay program, Wegovy is offered at $199 per month for the 0.25 mg and 0.5 mg starter doses through June 30, 2026, and $349 per month for the standard 0.25 mg through 2.4 mg pen doses. The Wegovy HD 7.2 mg pen runs $399 per month. With commercial insurance and a savings card, eligible patients pay as little as $25 per fill (capped at $100 per month maximum savings). For deeper coverage of Wegovy and Ozempic pricing, see our semaglutide cost guide.

Mounjaro (tirzepatide for type 2 diabetes)

Mounjaro is tirzepatide, manufactured by Eli Lilly, FDA-approved on May 13, 2022 for Type 2 diabetes.⁸ Unlike semaglutide, tirzepatide acts on two receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual mechanism is what produced the higher mean weight loss in head-to-head trials.

The brand-name list price is approximately $1,089.59 per 28-day supply. Patients with Type 2 diabetes and commercial insurance can pay $25 per fill with the Mounjaro savings card, with an annual cap of about $1,950 in maximum savings. For non-diabetic patients seeking weight loss, prescribers typically recommend Zepbound rather than off-label Mounjaro because the savings programs differ.

Zepbound (tirzepatide for weight loss and sleep apnea)

Zepbound is the same molecule as Mounjaro, branded for chronic weight management. FDA-approved on November 8, 2023 for obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition,⁹ and approved on December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity.¹⁰ The phase 3 SURMOUNT-1 trial randomized 2,539 adults with obesity to tirzepatide or placebo over 72 weeks; the 15 mg group lost an average of 20.9% of body weight versus 3.1% on placebo.¹¹

SURMOUNT-5, published in The New England Journal of Medicine in 2025, was the head-to-head trial comparing tirzepatide to semaglutide for obesity treatment in 751 adults without Type 2 diabetes. Over 72 weeks, tirzepatide produced a least-squares mean weight reduction of 20.2% compared with 13.7% for semaglutide (P<0.001).⁵ Zepbound's pricing is the most aggressive in the GLP-1 category: list price approximately $1,086 per month, but single-dose vials through LillyDirect Self Pay start at $299 per month for the 2.5 mg starter and step up to $499 to $699 per month for higher doses. With commercial insurance, the savings card brings eligible patients to $25 per fill. See our tirzepatide cost breakdown and semaglutide vs tirzepatide comparison.

Rybelsus (oral semaglutide)

Rybelsus is semaglutide in a daily oral tablet, manufactured by Novo Nordisk, FDA-approved on September 20, 2019 for Type 2 diabetes.¹² It is currently the only oral GLP-1 on the US market. The convenience comes with a tradeoff: bioavailability is lower than the injection, dosing is daily rather than weekly, and the tablet must be taken on an empty stomach with no more than 4 ounces of plain water, then waited 30 minutes before eating.

List price is approximately $997.58 per 30-tablet supply. Through NovoCare Pharmacy direct cash-pay, Rybelsus is offered at $149 per month for the 1.5 mg and 4 mg tablets, with the 4 mg intro price running through August 31, 2026. Patients who cannot tolerate weekly injections, or who prefer not to refrigerate a pen, sometimes choose Rybelsus.

Trulicity (dulaglutide)

Trulicity is dulaglutide, a once-weekly injectable GLP-1 from Eli Lilly, FDA-approved on September 18, 2014 for Type 2 diabetes,¹³ and later for cardiovascular risk reduction in adults with diabetes. It produces less mean weight loss than semaglutide or tirzepatide but has a longer track record and is sometimes preferred when cardiovascular outcomes are the primary goal.

Cash-pay list price is approximately $951.97 per pen. With insurance and the Trulicity savings card, eligible patients pay as little as $25 per fill.

Saxenda (liraglutide)

Saxenda is liraglutide, a daily injectable GLP-1 from Novo Nordisk, FDA-approved on December 23, 2014 for chronic weight management.¹⁴ The same molecule was sold for Type 2 diabetes under the brand Victoza, which lost patent protection in 2024; generic liraglutide is now available for diabetes but not yet for weight loss. In the SCALE trial, mean weight loss was around 5 to 8% of body weight at one year, smaller than semaglutide or tirzepatide.¹⁵

Saxenda's list price is approximately $1,349 per month. The daily injection schedule is the main reason patients now choose semaglutide or tirzepatide instead.

Compounded GLP-1 alternatives

Compounded semaglutide and compounded tirzepatide became the price-driven path in 2023 and 2024 when the FDA shortage list allowed pharmacies to legally produce copies of the branded drugs. The shortages ended on a clear timeline: the FDA declared the tirzepatide shortage resolved on December 19, 2024,¹⁶ and the semaglutide shortage resolved on February 21, 2025.¹⁷ The enforcement-discretion windows then closed: state-licensed 503A pharmacies had until April 22, 2025 to stop compounding semaglutide copies, and 503B outsourcing facilities had until May 22, 2025. In April 2026, the FDA further clarified that compounded semaglutide combined with vitamin B12 within 10 percent of commercial strength is treated as a copy of Wegovy or Ozempic, narrowing what licensed compounders can produce. A narrow exception remains for compounders filling four or fewer prescriptions of a given compounded product per calendar month.¹⁷

The relevant detail for cost-driven readers is that compounded GLP-1s did not disappear. They continue to be prescribed through telehealth providers and traditional pharmacies, typically with one or more of: a different formulation (oral troche, sublingual, or combined with B12, glycine, or carnitine within the four-Rx-per-month exception), patient-specific dosing, or a different active variant. Eli Lilly issued an open letter dated March 12, 2026 warning that combinations with B12 may produce a novel impurity from chemical reaction with tirzepatide,¹⁸ and the FDA has issued warning letters to specific compounders marketing copies without a valid pathway.

Compounded semaglutide

Typically prescribed through telehealth providers like Hims, Henry Meds, Mochi Health, and Sesame, with cash-pay pricing in the $200 to $500 per month range as of April 2026, where still available. Mechanism is identical to Ozempic and Wegovy. Risks center on potency variability and impurity content, both of which Lilly's published testing flagged for tirzepatide samples and which apply by extension to semaglutide. For full coverage of how the rules changed and what to ask a compounding pharmacy, see what is compounded semaglutide.

Compounded tirzepatide

Pricing in roughly the same $200 to $500 per month range, with the same mechanism as Mounjaro and Zepbound. The post-spring-2025 supply chain has narrowed to pharmacies producing combination or personalized formulations. The Lilly open letter dated March 12, 2026 warned about the B12 combination by name. See what is compounded tirzepatide for the full regulatory and safety picture.

How to vet a compounding pharmacy

• State licensing. The pharmacy should hold an active license in the patient's state, verifiable through the state board of pharmacy.
• 503A vs. 503B. 503A is patient-specific, prescribed for an individual. 503B is a registered outsourcing facility producing larger batches under FDA inspection. Both are legal; 503B has tighter manufacturing oversight.
• Third-party testing. Ask for certificates of analysis showing potency and impurity testing on each lot. Pharmacies that cannot produce these have a compliance problem.
• Active ingredient source. The active pharmaceutical ingredient (API) should come from an FDA-registered facility. API sourced from unregistered overseas suppliers is a red flag.

Our editorial coverage of specific telehealth providers (which prescribe and route to compounding pharmacies) lives at our reviews hub.

Non-GLP-1 prescription alternatives

For patients who want a prescription weight-loss medication but cannot tolerate or afford GLP-1s, three older options remain on the US market. They produce smaller mean weight loss than semaglutide or tirzepatide but cost less and have decades of safety data.

Contrave (naltrexone-bupropion)

Contrave combines naltrexone (an opioid antagonist used in addiction treatment) with bupropion (an antidepressant and smoking-cessation drug) in a single oral tablet. FDA-approved on September 10, 2014 for chronic weight management.¹⁹ Mean weight loss in the phase 3 COR-I trial was around 6.1% of body weight at one year for the high-dose group.²⁰ Cash-pay price is $99 per month through the manufacturer's CurAccess home-delivery program.

Contraindicated in seizure disorders, chronic opioid use, and uncontrolled hypertension. The most common side effects are nausea, constipation, headache, and insomnia.

Qsymia (phentermine-topiramate)

Qsymia combines phentermine (a stimulant appetite suppressant) with topiramate (an anticonvulsant). FDA-approved on July 17, 2012 for chronic weight management.²¹ Mean weight loss in the CONQUER trial was around 9.8% at one year for the top dose.²² Cash-pay price is approximately $98 per month through the manufacturer's home-delivery pharmacy.

The topiramate component requires women of reproductive age to use effective contraception because of teratogenicity risk. REMS (Risk Evaluation and Mitigation Strategy) applies.

Phentermine alone

Generic phentermine has been on the US market since 1959, FDA-approved for short-term (up to 12 weeks) use as an adjunct to lifestyle changes. It is the cheapest prescription weight-loss option, often $15 to $40 per month at retail pharmacies. Mean weight loss is modest, around 3 to 5% of body weight in short-term trials, and rebound is common after discontinuation. Stimulant side effects (insomnia, dry mouth, raised heart rate) and DEA Schedule IV controlled-substance status limit who can take it.

Over-the-counter and natural options

The natural-alternatives category is where the keyword search divides most sharply between marketing claims and clinical evidence. Three options have at least some data; the rest are positioning.

Berberine

Berberine is an alkaloid extracted from plants including Berberis vulgaris (barberry), Coptis chinensis (Chinese goldthread), and Hydrastis canadensis (goldenseal). The viral "Nature's Ozempic" label oversells the evidence, but the evidence is not zero. The 2015 meta-analysis by Lan et al. in the Journal of Ethnopharmacology found that berberine lowered fasting blood glucose, HbA1c, and serum lipids in adults with Type 2 diabetes, with effect sizes comparable to first-line oral antidiabetics like metformin and far smaller than GLP-1 agonists.²³

Several caveats apply. Most studies in that meta-analysis were small, conducted in China, and used varied dosing (typically 500 mg two or three times daily). Berberine has poor oral bioavailability, interacts with many drugs through CYP enzyme inhibition (statins, blood thinners, some antibiotics), and commonly causes GI side effects. It is sold as a dietary supplement in the US, which means manufacturing oversight is lighter than for FDA-approved drugs. Cost runs $15 to $40 per month for a quality-tested brand.

The bottom line: berberine has more evidence than any other supplement marketed as an Ozempic alternative, but its clinical effect is closer to metformin than to semaglutide, and the supplement-grade quality control is uneven.

BRP, the Stanford research peptide

On March 5, 2025, Stanford Medicine researchers led by Katrin Svensson, PhD, with lead author Laetitia Coassolo, PhD, published in Nature the discovery of a 12-amino-acid peptide they called BRP (BRINP2-related-peptide).⁶ In animal trials, a single injection cut food intake by up to 50% in mice and minipigs over the following hour, and obese mice injected daily for 14 days lost an average of 3 grams of fat while controls gained 3 grams. BRP appeared to work without nausea, constipation, or significant muscle loss because it acts only in the hypothalamus rather than on receptors throughout the body the way semaglutide does.

This is research-stage. BRP is not a drug, not approved, not in human trials at the time of publication, and not commercially available. Anything sold as "BRP" online today is not the Stanford molecule. The reason we include it here is that it sets the upper bound on what natural-alternative coverage realistically looks like in 2026: a peer-reviewed peptide discovery, years away from approval.

Fiber, protein, and the high-satiety eating pattern

The mechanism behind GLP-1 drugs (slowed gastric emptying plus stronger satiety hormone signaling) overlaps with the mechanism behind certain dietary patterns. Higher-protein meals (≥30 grams per meal), soluble fiber (psyllium husk, oats, beans, chia), and adequate sleep all raise satiety hormones (PYY, leptin) and reduce next-meal intake in randomized feeding studies. None of these produce the 15 to 20% mean weight loss that GLP-1 trials measure, but the cost is near zero and the side effect profile is favorable. They are also the lifestyle recommendations every GLP-1 trial protocol pairs with the medication, so framing them as "alternative" misreads how the medication category was tested.

How the prices stack up

The table below shows monthly cash-pay cost ranges for each option as of April 27, 2026, with the cheapest legitimate path on the left and brand-name retail on the right.

How to choose

The right alternative depends on what is actually driving the search. A short decision framework:

• If cost is the primary issue and you want a GLP-1. Compounded semaglutide or tirzepatide through a state-licensed pharmacy is the cheapest legal path in 2026. Vet the pharmacy on licensing, third-party testing, and API source. If brand-name is preferred, Zepbound vials through LillyDirect Self Pay at $299 starter dose, or Wegovy through NovoCare direct at $199 starter (through June 30, 2026), are the lowest cash-pay branded options.
• If insurance covers GLP-1s for diabetes but not weight loss. Ozempic, Mounjaro, Trulicity, or Rybelsus at $25 with the savings card are reasonable. Discuss with your prescriber which is appropriate.
• If insurance covers weight-loss medications. Wegovy or Zepbound at $25 with the savings card. Tirzepatide produced higher mean weight loss in the SURMOUNT-5 head-to-head trial (20.2% vs. 13.7% over 72 weeks).
• If you cannot tolerate GLP-1 side effects. Contrave or Qsymia have decades of data, smaller mean weight loss (around 6 to 10%), and lower cost. Phentermine is short-term only.
• If you prefer non-prescription. Berberine has the most clinical evidence but produces effects closer to metformin than to semaglutide. Pair with a high-protein, high-fiber eating pattern. Talk to a prescriber if you have diabetes or take any prescription medication, since berberine has many drug interactions.

The framing of this whole search query, that there is some "Ozempic alternative" out there waiting to be discovered, undersells the situation. The category has expanded. The decisions are tradeoffs between cost, evidence strength, regulatory pathway, and side effect tolerability, not between "real" and "fake" options.

FAQ

What is the closest alternative to Ozempic?

Wegovy is the closest match because it is the same molecule (semaglutide) made by the same manufacturer (Novo Nordisk), only at a higher dose and with an FDA indication for weight management rather than Type 2 diabetes. For non-semaglutide options, Mounjaro and Zepbound (tirzepatide) are dual GLP-1/GIP agonists. In the SURMOUNT-5 head-to-head trial published in NEJM 2025, tirzepatide produced a mean 20.2% body weight reduction at 72 weeks compared with 13.7% for semaglutide.

Is there a cheaper alternative to Ozempic?

Brand-name Ozempic lists at $1,027.51 per fill before discounts. The cheapest brand-name path in 2026 is Zepbound single-dose vials through LillyDirect Self Pay starting at $299 per month, or Wegovy through NovoCare Pharmacy direct cash-pay at $199 per month for the starter doses (through June 30, 2026) and $349 per month for standard pens. With commercial insurance and a manufacturer savings card, eligible patients can pay $25 per fill, but coverage for off-label weight loss is less common than for Type 2 diabetes.

Are there natural alternatives to Ozempic that work?

Berberine has the most clinical evidence among supplements marketed as natural Ozempic alternatives. The Lan et al. 2015 meta-analysis in the Journal of Ethnopharmacology found that berberine lowered fasting blood glucose, HbA1c, and lipids in adults with Type 2 diabetes, with effect sizes comparable to metformin and much smaller than GLP-1 agonists. The viral "Nature's Ozempic" label oversells the evidence. A peptide called BRP, identified by Stanford researchers in March 2025 and published in Nature, suppressed appetite in mice and minipigs without nausea but is not in human trials.

Can I switch from Ozempic to a different GLP-1?

Yes, with a prescriber. Switching from semaglutide to tirzepatide (or vice versa) typically restarts at the lower-dose end of the new ladder rather than matching milligrams, because the molecules differ. Switching from Ozempic to Wegovy is the simplest case because it is the same active ingredient, only at a higher maintenance dose. Discuss timing, dose, and side effect history with your prescriber rather than self-switching, especially if you have Type 2 diabetes.

Why do people look for Ozempic alternatives?

The most common reasons in 2026 are cost (brand-name Ozempic lists at $1,027.51 per pen without insurance), insurance denials for off-label weight loss use, supply intermittency that left patients hunting refills in 2023 to 2025, side effect tolerability (nausea, GI symptoms), and a preference for compounded or oral options. The "Ozempic alternatives" search query runs about 16,000 monthly US searches per Ahrefs and is concentrated on cost and access, not safety panic.

Is compounded semaglutide still legal in 2026?

Yes, in a narrower regulatory window than in 2023 to 2024. Direct copies of branded Ozempic or Wegovy are no longer broadly permitted from 503A pharmacies after the April 22, 2025 enforcement-discretion deadline (May 22, 2025 for 503B outsourcing facilities). State-licensed 503A and registered 503B pharmacies still produce personalized or combination semaglutide formulations under a narrower pathway, with a four-prescription-per-month exception for compounded products. Lilly and Novo Nordisk have warned about specific combinations (such as tirzepatide with B12) that may produce novel impurities.